These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32206807)

  • 1. Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease.
    Orfanoudaki E; Foteinogiannopoulou K; Theodoraki E; Koutroubakis IE
    Inflamm Bowel Dis; 2020 May; 26(6):e50. PubMed ID: 32206807
    [No Abstract]   [Full Text] [Related]  

  • 2. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
    Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring.
    Lucidarme C; Petitcollin A; Brochard C; Siproudhis L; Dewitte M; Landemaine A; Bellissant E; Bouguen G
    Aliment Pharmacol Ther; 2019 Jan; 49(2):147-154. PubMed ID: 30589970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.
    Fernandes SR; Bernardo S; Simões C; Gonçalves AR; Valente A; Baldaia C; Moura Santos P; Correia LA; Tato Marinho R
    Inflamm Bowel Dis; 2020 Jan; 26(2):263-270. PubMed ID: 31247074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
    Van Stappen T; Vande Casteele N; Van Assche G; Ferrante M; Vermeire S; Gils A
    Gut; 2018 May; 67(5):818-826. PubMed ID: 28450388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
    Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
    Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease.
    Bevers NC; Keizer RJ; Wong DR; Aliu A; Pierik MJ; Derijks LJJ; van Rheenen PF
    Clin Pharmacokinet; 2024 Apr; 63(4):529-538. PubMed ID: 38488984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease.
    Curci D; Lucafò M; Cifù A; Bramuzzo M; Martelossi S; Favretto D; De Pellegrin F; Fabris M; Vascotto F; Naviglio S; Ventura A; Stocco G; Decorti G
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):474-479. PubMed ID: 31149938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
    Wong U; Cross RK
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1039-1046. PubMed ID: 28876147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.
    Amiot A; Hulin A; Belhassan M; Andre C; Gagniere C; Le Baleur Y; Farcet JP; Delchier JC; Hüe S
    Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):90-8. PubMed ID: 26138132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels.
    Novakovic V; Abdija S; Larsen PB; Fenger M; Gredal L; Jacobsen KK
    Clin Biochem; 2019 Dec; 74():73-75. PubMed ID: 31669514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):847-853. PubMed ID: 30633108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab.
    Scaldaferri F; D'Ambrosio D; Holleran G; Poscia A; Petito V; Lopetuso L; Graziani C; Laterza L; Pistone MT; Pecere S; Currò D; Gaetani E; Armuzzi A; Papa A; Cammarota G; Gasbarrini A
    PLoS One; 2017; 12(10):e0186575. PubMed ID: 29073159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design.
    Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N
    Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
    Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA
    Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.
    Papamichael K; Vajravelu RK; Osterman MT; Cheifetz AS
    Dig Dis Sci; 2018 Mar; 63(3):761-767. PubMed ID: 29340807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW;
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1037-1053. PubMed ID: 29027257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center.
    Orlando A; Renna S; Rizzuto G; Orlando E; Affronti M; Cottone M
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):914. PubMed ID: 26707682
    [No Abstract]   [Full Text] [Related]  

  • 20. Higher Infliximab Levels Are Not Associated With an Increase in Adverse Events in Inflammatory Bowel Disease.
    Greener T; Kabakchiev B; Steinhart AH; Silverberg MS
    Inflamm Bowel Dis; 2018 Jul; 24(8):1808-1814. PubMed ID: 29697810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.